STAT3 and cancer: A dihydroimidazolone derivative, napabukasin (BBI-608), has been tested in clinical trials to reduce the activity of STAT3-dependent genes in cancer cells; however, its mechanism is not entirely clear, and it is believed to act as a proxy killer of STAT3-activated cells [180,181,182].